Skip to main content
. 2022 May 26;11(24):4889–4899. doi: 10.1002/cam4.4820

FIGURE 2.

FIGURE 2

Primary analysis of individual patient responses to liso‐cel over time. aThe first dot represents the actual assessment date on or around day 29. bOne patient was diagnosed with secondary CNS lymphoma after screening and achieved a CR as a best overall response and was alive at the last assessment. CNS, central nervous system; CR, complete response; IRC, independent review committee; liso‐cel, lisocabtagene maraleucel; PD, progressive disease; PR, partial response